Clinical Convergence® Unresectable HCC: An Emerging Era of Combination Therapy

Proprietary Educational Format:

Activity Overview

In this web-based CME activity, experts discuss recent developments in the treatment of hepatocellular carcinoma (HCC). Do not miss this opportunity to learn more about new and emerging combination strategies and receive practical guidance on their integration into clinical practice.

You will hear first-hand from an experienced patient with HCC who will share his personal journey and offer a novel perspective for healthcare professionals.

0.75 CE Credit(s)
Expires: December 28, 2021

Target Audience

This activity is intended for hepatology, hematology/oncology, and other clinicians including physicians, NPs, and PAs who diagnose and manage patients with hepatocellular carcinoma (HCC).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Develop treatment plans for patients with advanced hepatocellular carcinoma (HCC) that integrate checkpoint inhibitors and targeted synthetic agents based on their efficacy and safety data
  • Develop individualized treatment plans for patients with advanced HCC across multiple lines of therapy
  • Analyze the safety and efficacy of new and emerging combination regimens for HCC

 

Activity Faculty

Finn-MS

Richard S. Finn, MD

Professor, Department of Medicine​
Division of Hematology/Oncology​
UCLA David Geffen School of Medicine ​
Director, Signal Transduction and Therapeutics Program​
Jonsson Comprehensive Cancer Center ​
University of California ​
Los Angeles, CA

Singal-MS

Amit Singal, MD, MS  

David Bruton Jr. Professor, Clinical Cancer Research
Professor, Medicine
Chief and Medical Director, Liver Tumor Program
UT Southwestern Medical Center
Dallas, TX

Yarchoan-MS

Mark Yarchoan, MD

Assistant Professor, Division of GI Malignancies
Medical Oncology Director, Liver Cancer Multidisciplinary Clinic
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, MD